Brain connectivity as a new target for Alzheimer’s disease therapy?
Brain · 07.02.2026 · 149 (2) · 432-438
DOI: 10.1093/brain/awaf404 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Brain, online erschienen am 28.11.2025. Verfasst von Lorenzo Pini und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, University of Padova, Padova 35123 Italy. Hauptthemen laut MEDLINE: Alzheimer Disease, Brain, Nerve Net. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 64 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
The recent introduction of immunotherapeutic agents targeting amyloid-β (Aβ) has advanced the pharmacological treatment of Alzheimer’s disease (AD). Although several anti-Aβ antibodies have dramatically reduced cerebral amyloid plaques, this has not translated into major cognitive or clinical benefits, thus questioning the clinical relevance of these biomarker changes. Indeed, there is an ongoing debate over whether amyloid reduction alone constitutes sufficient evidence of disease modification to justify regulatory approval. Against this backdrop, we propose a third pathway that transcends the binary framework of molecular versus clinical end points by positioning brain connectivity as a system-level intermediate phenotype. This approach is supported by a growing body of evidence. Alterations in brain networks are early, sensitive, and modifiable markers of AD pathology. Connectivity metrics capture the dynamic interplay between genetic and environmental factors, offering a unified model of disease. Advances in precision medicine, such as individualized connectivity ‘fingerprints’ and the emergence of digital twins, further position brain connectivity as a powerful platform for therapeutic innovation. We argue that adopting brain network analysis as a key outcome measure enables a shift beyond isolated biomarker achievements toward a more integrated, biologically grounded, and clinically meaningful framework for disease modification in AD, bridging the gap between molecular advances and real-world impact.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuroscience, University of Padova, Padova 35123 Italy.
- Padova Neuroscience Center, University of Padova, Padova 35123 Italy.
- Leenaards Memory Center, Lausanne University Hospital and University of Lausanne, Lausanne 1011, Switzerland.
- Department of Research and Development, Chiesi Farmaceutici, Parma 43122, Italy.
- Veneto Institute of Molecular Medicine (VIMM), Padova 35123, Italy.
ORCID-Profile: Lorenzo Pini, Gilles Allali, Bruno P Imbimbo
Zitieren
APA
Pini, L., Allali, G., Imbimbo, B. P., Germani, M., & Corbetta, M. (2026). Brain connectivity as a new target for Alzheimer’s disease therapy?. Brain, 149(2), 432-438. https://doi.org/10.1093/brain/awaf404
Vancouver
Pini L, Allali G, Imbimbo BP, Germani M, Corbetta M. Brain connectivity as a new target for Alzheimer’s disease therapy?. Brain. 2026;149(2):432-438. doi:10.1093/brain/awaf404
BibTeX
@article{Pini2026,
author = {Pini, Lorenzo and Allali, Gilles and Imbimbo, Bruno P and Germani, Massimiliano and Corbetta, Maurizio},
title = {Brain connectivity as a new target for Alzheimer’s disease therapy?},
journal = {Brain},
year = {2026},
volume = {149},
number = {2},
pages = {432--438},
doi = {10.1093/brain/awaf404}
}
EUVIMED